ArticleFrontiers in immunology2023
Potential bioactivities via anticancer, antioxidant, and immunomodulatory properties of cultured mycelial enriched β-D-glucan polysaccharides from a novel fungus
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Water-soluble sulfated exopolysaccharide from Cytobacillus oceanisediminis: Its production, characterization and biological activities.Folia microbiologica · 2026Article
- Deciphering the anticancer potential of an entomopathogenic fungus, Cordyceps militaris in Dalton's Lymphoma transplanted murine model: a multidimensional approach involving computational methods and in vivo validation.Molecular and cellular biochemistry · 2026Article
- Acid Degradation, Structure Characterization of a Novel Polysaccharide from Leaves ofMolecules (Basel, Switzerland) · 2026Article
- Pleiotropic Bioactivity of Caterpillar Fungus, Orange Cordyceps, and Cordycepin: Insight from Integrated Network Pharmacology and Food and Drug Regulatory Framework.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Pyrimidine-containing natural products: occurrences and biological activities.Natural products and bioprospecting · 2026Review
- Article
- Computational and experimental discovery of peptide inhibitors targeting survivin for therapeutic potential in cancer.Scientific reports · 2025Article
- Comparative evaluation of free radical scavenging activity and total metabolite profiles among 30 macrofungi species.Bioresources and bioprocessing · 2025Article
- Visualized Nucleic Acid Hybridization Lateral Flow Strip Integrating with Microneedle for the Point-of-Care Authentication ofInternational journal of molecular sciences · 2024Article
- Extraction Optimization, Structural Analysis, and Potential Bioactivities of a Novel Polysaccharide fromAntioxidants (Basel, Switzerland) · 2024Article
- The Anti-Inflammatory Effects and Mechanism of the Submerged Culture ofJournal of fungi (Basel, Switzerland) · 2024Article
- Rapid discrimination between wild and cultivatedCurrent research in food science · 2024Article
- Characterization of Metabolite Landscape Distinguishes Medicinal FungusMolecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: We investigated the potential bioactivities via anticancer, antioxidant, and immunomodulatory polysaccharides (OS8P) produced from cultured mycelia of Results: The yield of mycelial biomass was 23.61 g/l, and it contained 306.1 mg/100 g of adenosine and 3.22 g/100 g of polysaccharides. This OS8P was enriched with β-D-glucan at 56.92% and another form of α-D-glucan at 35.32%. The main components of OS8P were dodecamethyl pentasiloxane, 2,6-bis (methylthiomethyl) pyridine, 2-(4-pyrimidinyl)-1H-Benzimidazole, and 2-Chloro-4-(4-nitroanilino)-6-(O-toluidino)-1,3,5-triazine at the rates of 32.5, 20.0, 17.5, and 16.25%, respectively. The growth of colon cancer cells (HT-29) was significantly inhibited by OS8P, with IC Conclusion: The OS8P enriched with β-D-glucan polysaccharides and produced by submerged mycelial culture of a new fungal strain of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.